These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 27829371)

  • 21. Propensity scores used for analysis of cluster randomized trials with selection bias: a simulation study.
    Leyrat C; Caille A; Donner A; Giraudeau B
    Stat Med; 2013 Aug; 32(19):3357-72. PubMed ID: 23553813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Comparison of Matching and Weighting Methods for Causal Inference Based on Routine Health Insurance Data, or: What to do If an RCT is Impossible.
    Matschinger H; Heider D; König HH
    Gesundheitswesen; 2020 Mar; 82(S 02):S139-S150. PubMed ID: 32066197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interval-cohort designs and bias in the estimation of per-protocol effects: a simulation study.
    Young JG; Vatsa R; Murray EJ; Hernán MA
    Trials; 2019 Sep; 20(1):552. PubMed ID: 31488202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin.
    Seeger JD; Bykov K; Bartels DB; Huybrechts K; Schneeweiss S
    Drug Saf; 2017 Feb; 40(2):169-181. PubMed ID: 27900668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating causal effects from a randomized clinical trial when noncompliance is measured with error.
    Boatman JA; Vock DM; Koopmeiners JS; Donny EC
    Biostatistics; 2018 Jan; 19(1):103-118. PubMed ID: 28605411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial.
    Stewart AK; Vescio R; Schiller G; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; White M; DiPersio J; Anderson KC; Berenson J
    J Clin Oncol; 2001 Sep; 19(17):3771-9. PubMed ID: 11533101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
    Malard F; Harousseau JL; Mohty M
    Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.
    Shi Q; Flowers CR; Hiddemann W; Marcus R; Herold M; Hagenbeek A; Kimby E; Hochster H; Vitolo U; Peterson BA; Gyan E; Ghielmini M; Nielsen T; De Bedout S; Fu T; Valente N; Fowler NH; Hoster E; Ladetto M; Morschhauser F; Zucca E; Salles G; Sargent DJ
    J Clin Oncol; 2017 Feb; 35(5):552-560. PubMed ID: 28029309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
    Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
    Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry.
    Offidani M; Corvatta L; Polloni C; Centurioni R; Visani G; Brunori M; Gentili S; Catarini M; Samori A; Blasi N; Alesiani F; Caraffa P; Burattini M; Galieni P; Fraticelli P; Ferranti M; Giuliodori L; Leoni P
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):423-32. PubMed ID: 22981966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marginal mean weighting through stratification: a generalized method for evaluating multivalued and multiple treatments with nonexperimental data.
    Hong G
    Psychol Methods; 2012 Mar; 17(1):44-60. PubMed ID: 21843003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statistical inference for time-to-event data in non-randomized cohorts with selective attrition.
    Wang T; Mao L; Cocco A; Kim K
    Stat Med; 2024 Jan; 43(2):216-232. PubMed ID: 37957033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic temperature modulation in severe or moderate traumatic brain injury: a propensity score analysis of data from the Nationwide Japan Neurotrauma Data Bank.
    Miyata K; Ohnishi H; Maekawa K; Mikami T; Akiyama Y; Iihoshi S; Wanibuchi M; Mikuni N; Uemura S; Tanno K; Narimatsu E; Asai Y
    J Neurosurg; 2016 Feb; 124(2):527-37. PubMed ID: 26381247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical power in parallel group point exposure studies with time-to-event outcomes: an empirical comparison of the performance of randomized controlled trials and the inverse probability of treatment weighting (IPTW) approach.
    Austin PC; Schuster T; Platt RW
    BMC Med Res Methodol; 2015 Oct; 15():87. PubMed ID: 26472109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials.
    Joosse A; Collette S; Suciu S; Nijsten T; Patel PM; Keilholz U; Eggermont AM; Coebergh JW; de Vries E
    J Clin Oncol; 2013 Jun; 31(18):2337-46. PubMed ID: 23690423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma.
    Wildes TM; Finney JD; Fiala M; Gao F; Vij R; Stockerl-Goldstein K; Carson KR; Mikhael J; Colditz G
    Bone Marrow Transplant; 2015 Aug; 50(8):1075-82. PubMed ID: 25961765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survivor treatment selection bias and outcomes research: a case study of surgery in infective endocarditis.
    Sy RW; Bannon PG; Bayfield MS; Brown C; Kritharides L
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):469-74. PubMed ID: 20031879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.